Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Post-Transplant Cyclophosphamide GVHD Prophylaxis Has a Unique Vascular Toxicity Compared to Abatacept Containing Regimens. | Synapse
March 3, 2026
Post-Transplant Cyclophosphamide GVHD Prophylaxis Has a Unique Vascular Toxicity Compared to Abatacept Containing Regimens.
PB
Priscila Badia
Cincinnati Children's Hospital Medical Center
LL
Lucille Langenberg
AI
Azada Ibrahimova
Cincinnati Children's Hospital Medical Center
Ver todo
Puntos clave
Cyclophosphamide prophylaxis is associated with distinct vascular toxicity compared to abatacept-based regimens.
Graft-versus-host disease (GVHD) prophylaxis was assessed in patients receiving different treatments, focusing on vascular effects.
Observational analysis focuses on cytokine levels and their relation to vascular toxicity in transplant settings.
Understanding these toxicities may guide clinicians in selecting appropriate GVHD prophylactic strategies.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Badia et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76043c6e9836116a2cd4c
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.884
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir